Informative Note
Initial assessment of the impact of possible legislative changes in the pharmaceutical sector
21/04/2021Share
The COVID-19 pandemic has exposed the difficulties in reacting at European level to a major health crisis and the intention of the European Commission is to respond more effectively to future problems in the area of health. As a result, it is currently conducting an initial assessment of possible legislative changes in the area of medicinal products for human use.
The aim of the legislative changes is to make the European rules more adaptable to new technological developments, to achieve sustainability in production and accessibility to medicines and, above all, to simplify EU procedures relating to medicines. The industry now has the opportunity, until 27 April, to have its say and to help shape the Commission's initial proposal.
